Literature DB >> 22155302

Withanone binds to mortalin and abrogates mortalin-p53 complex: computational and experimental evidence.

Abhinav Grover1, Didik Priyandoko, Ran Gao, Ashutosh Shandilya, Nashi Widodo, Virendra S Bisaria, Sunil C Kaul, Renu Wadhwa, Durai Sundar.   

Abstract

Mortalin binds to p53 tumor suppressor protein and sequesters it in the cytoplasm. This results in an inhibition of the transcriptional activation and control of centrosome duplication functions of p53, thus contributing to human carcinogenesis. Abrogation of mortalin-p53 interaction and reactivation of p53 function could be a valid proposition for cancer therapy. In the present study, we first investigated in silico the interaction of withanone, a withanolide with anticancer activity, with mortalin. We found that withanone could bind to mortalin in a region, earlier predicted critical for binding to p53. Cationic rhodacyanine dye, MKT-077 has also shown to bind the same region and kill cancer cells selectively. We report the molecular dynamic simulations revealing the thermodynamic and structural stability of the withanone-mortalin complexes. We also demonstrate the experimental evidence of abrogation of mortalin-p53 complex by withanone resulting in nuclear translocation and functional reactivation of p53 in human cancer cells. The present study establishes a molecular interaction basis that could be used for screening and development of anticancer drugs with low toxicity to normal cells. Accurate knowledge of the 3D structure of mortalin would further enhance the potential of such analyses to understand the molecular basis of mortalin biology and mortalin based cancer therapy.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22155302     DOI: 10.1016/j.biocel.2011.11.021

Source DB:  PubMed          Journal:  Int J Biochem Cell Biol        ISSN: 1357-2725            Impact factor:   5.085


  23 in total

1.  2- and N6-functionalized adenosine-5'-diphosphate analogs for the inhibition of mortalin.

Authors:  Mitchell A Moseng; Jay C Nix; Richard C Page
Journal:  FEBS Lett       Date:  2019-06-18       Impact factor: 4.124

Review 2.  TPX2: of spindle assembly, DNA damage response, and cancer.

Authors:  Gernot Neumayer; Camille Belzil; Oliver J Gruss; Minh Dang Nguyen
Journal:  Cell Mol Life Sci       Date:  2014-02-21       Impact factor: 9.261

3.  Structural studies of UBXN2A and mortalin interaction and the putative role of silenced UBXN2A in preventing response to chemotherapy.

Authors:  Sanam Sane; Ammara Abdullah; Morgan E Nelson; Hongmin Wang; Subhash C Chauhan; Samuel S Newton; Khosrow Rezvani
Journal:  Cell Stress Chaperones       Date:  2015-12-04       Impact factor: 3.667

4.  Anti-Stress and Glial Differentiation Effects of a Novel Combination of Cucurbitacin B and Withanone (CucWi-N): Experimental Evidence.

Authors:  Sukant Garg; Sunil C Kaul; Renu Wadhwa
Journal:  Ann Neurosci       Date:  2018-07-05

5.  Differential activities of the two closely related withanolides, Withaferin A and Withanone: bioinformatics and experimental evidences.

Authors:  Kirti Vaishnavi; Nishant Saxena; Navjot Shah; Rumani Singh; Kavyashree Manjunath; M Uthayakumar; Shankar P Kanaujia; Sunil C Kaul; Kanagaraj Sekar; Renu Wadhwa
Journal:  PLoS One       Date:  2012-09-04       Impact factor: 3.240

6.  Molecular interactions of Bcl-2 and Bcl-xL with mortalin: identification and functional characterization.

Authors:  Nishant Saxena; Shashank P Katiyar; Ye Liu; Abhinav Grover; Ran Gao; Durai Sundar; Sunil C Kaul; Renu Wadhwa
Journal:  Biosci Rep       Date:  2013-10-16       Impact factor: 3.840

7.  SHetA2 interference with mortalin binding to p66shc and p53 identified using drug-conjugated magnetic microspheres.

Authors:  Doris Mangiaracina Benbrook; Baskar Nammalwar; Andrew Long; Hiroyuki Matsumoto; Anil Singh; Richard A Bunce; K Darrell Berlin
Journal:  Invest New Drugs       Date:  2013-11-20       Impact factor: 3.850

8.  Combinations of Ashwagandha leaf extracts protect brain-derived cells against oxidative stress and induce differentiation.

Authors:  Navjot Shah; Rumani Singh; Upasana Sarangi; Nishant Saxena; Anupama Chaudhary; Gurcharan Kaur; Sunil C Kaul; Renu Wadhwa
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

9.  Blocking protein kinase C signaling pathway: mechanistic insights into the anti-leishmanial activity of prospective herbal drugs from Withania somnifera.

Authors:  Abhinav Grover; Shashank Prakash Katiyar; Jeyaraman Jeyakanthan; Vikash Kumar Dubey; Durai Sundar
Journal:  BMC Genomics       Date:  2012-12-13       Impact factor: 3.969

10.  Ubiquitin-like (UBX)-domain-containing protein, UBXN2A, promotes cell death by interfering with the p53-Mortalin interactions in colon cancer cells.

Authors:  S Sane; A Abdullah; D A Boudreau; R K Autenried; B K Gupta; X Wang; H Wang; E H Schlenker; D Zhang; C Telleria; L Huang; S C Chauhan; K Rezvani
Journal:  Cell Death Dis       Date:  2014-03-13       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.